A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)

  • Cancer
  • Breast Cancer
  • HER2‑Positive Breast Cancer
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Completed

This trial runs in
Countries
  • Austria
  • Bulgaria
  • Italy
  • Portugal
  • Romania
Trial Identifier:

NCT02913456 MO39146

  • Lkh-Univ. Klinikum Graz; Klinik Für Gynäkologie

    8036GrazAustria
  • LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie

    8036GrazAustria
  • Klinikum Klagenfurt; Abt. f. Hämatologie u. internistische Onkologie

    9020Klagenfurt am WörtherseeAustria
  • LKH Hochsteiermark; Abt. für Hämato-Onkologie

    8700LeobenAustria
  • Ordensklinikum Linz Elisabethinen ; I. INTERNE ABT.

    4020LinzAustria
  • A.Ö. Krankenhaus Der Barmherzigen Schwestern Ried; Interne Abtl.

    4910Ried im InnkreisAustria
  • A.Ö. Lhk Villach; Abt. Für Gynäkologie

    9500VillachAustria
  • Landesklinikum Wiener Neustadt; Innere Medizin, Hämatologie u. internistische Onkologie

    2700wiener-neustadtAustria
  • Medizinische Universität Wien; Univ.Klinik für Frauenheilkunde - Klinik für Gynäkologie

    1090WienAustria
  • Medizinische Universität Wien; Univ.Klinik für Innere Medizin I

    1090WienAustria
  • Hanusch-Krankenhaus; Geburtshilfliche und Gynäkologische Abteilung

    1140WienAustria
  • Multiprofile Hospital for Active Treatment Central Onco Hospital OOD

    PlovdivBulgaria
  • Complex Oncological Center - Plovdiv, EOOD

    4004PlovdivBulgaria
  • Mdozs - Russe

    7000RuseBulgaria
  • MHAT Nadezhda

    1330SofiaBulgaria
  • Tokuda Hospital; Medical Oncology Department

    1407SofiaBulgaria
  • University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL EAD

    1527SofiaBulgaria
  • SHATOD - Sofia

    1784SofiaBulgaria
  • Complex Oncology Center-Burgas; Medical Oncology

    SofiaBulgaria
  • District Oncology Dispensary; Dept of Chimiotherapy

    Stara ZagoraBulgaria
  • District Oncology Dispensary Wit Stationary

    9010VarnaBulgaria
  • Comprehensive Oncology Center - Vratsa

    VratsaBulgaria
  • A.O. Universitaria Policlinico Di Modena; Oncologia

    41124ModenaItaly
  • RCCS - Centro di Riferimento; Oncologia Medica B

    33081friuli-venezia-giuliaItaly
  • Ospedale S. Maria Goretti; Divisione Di Oncologia Medica

    04100LatinaItaly
  • Ospedale S.S. Trinità Nuovo; Divisione Oncologia

    03039SoraItaly
  • Ospedale Belcolle Di Viterbo; Oncologia

    01100ViterboItaly
  • Az. Osp. Spedali Civili; Divisione Di Oncologia - Iii Medicina

    25123BresciaItaly
  • A.O.U. Ospedali Riuniti Umberto I-G.M.Lancisi-G.Salesi Ancona;S.O.D. MED.Interna-Clinica Oncologica

    60123AnconaItaly
  • Ospedale Degli Infermi Di Biella; Reparto Oncologia Medica

    13875piemonteItaly
  • Irccs Ist. Tumori Giovanni Paolo Ii; Dipartimento Oncologia Medica

    70124BariItaly
  • Ospedale Barletta - Mons. Dimiccoli; Dip. Oncologia

    76121
  • Ospedale Cannizzaro, Oncologia

    95126CataniaItaly
  • Casa Di Cura Di Alta Specialita La Maddalena; Dept. Oncologico Di Iii Livello

    90146PalermoItaly
  • Azienda Ospedaliero-Universitaria Careggi; SOD Radioterapia

    50134FlorenceItaly
  • Ospedale San Luca; Oncologia

    55100LuccaItaly
  • Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica

    06129PerugiaItaly
  • Ospedale Civile; Oncologia Medica

    35012CamposampieroItaly
  • Azienda Ospedaliero Universitaria di Ferrara - U.O. Di Oncologia

    44124ConaItaly
  • Azienda ULSS 21 Ospedale Mater Salutis; Dip. di Oncologia

    37045LegnagoItaly
  • A.O.U. Integrata Verona - Policlinico G.B. Rossi; Oncologia Medica - Dip. di Medicina

    37126VeronaItaly
  • Hospital Garcia de Orta; Servico de Oncologia Medica

    AlmadaPortugal
  • IPO de Coimbra; Servico de Oncologia Medica

    3000-075CoimbraPortugal
  • Hospital Santo Antonio dos Capuchos;Servico de Oncologia Medica

    1169-050LisboaPortugal
  • Hospital de Santa Maria; Servico de Oncologia Medica

    1649-028LisboaPortugal
  • Hospital Beatriz Angelo; Departamento de Oncologia

    2670LouresPortugal
  • IPO do Porto; Servico de Oncologia Medica

    4200-072PortoPortugal
  • County Hospital Alba; Oncology

    Alba IuliaRomania
  • "Filantropia" Clinical Hospital; Gynecological Oncology

    011132BucureștiRomania
  • Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti

    BucureștiRomania
  • Prof. Dr. I. Chiricuta Institute of Oncology

    400015Cluj-NapocaRomania
  • Cluj-Napoca Emergency Clinical County Hospital; Medical Oncology

    Cluj-NapocaRomania
  • Centrul de Oncologie Sfantul Nectarie

    CraiovaRomania
  • Oncomed SRL

    TimișoaraRomania
    Show trial locations

    The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

    The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

    Results Disclaimer

    Trial Summary

    This disease registry is a prospective, multicenter non-interventional study designed to observe anti-cancer treatment regimens and clinical outcomes in participants with HER2-positive unresectable LA/mBC. Diagnosis of unresectable LA or mBC can be up to 6 months old prior to registry enrollment.

    Hoffmann-La Roche Sponsor
    N/A Phase
    NCT02913456, MO39146 Trial Identifier
    Breast Cancer Condition
    Official Title

    A European Disease Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

    Eligibility Criteria

    All Gender
    ≥ 18 Years Age
    No Healthy Volunteers
    Inclusion Criteria
    • Initially diagnosed with HER2-positive unresectable LA/mBC no more than 6 months prior to enrollment, although they can have received anti-cancer treatment during that time
    Exclusion Criteria
    • Not applicable

    Clinical Research Explained

    Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

    Find out now